Company profile
Upsher-Smith Laboratories, LLC
6472 · Taiwan Stock Exchange (also OTC: BORAY) (Not on the roster. Ownership chain: privately held by the Evenstad family (via ACOVA, Inc.) through 2017 -> generics business acquired by Sawai Pharmaceutical Co., Ltd. (Japan) in 2017, with Sumitomo Corporation later taking a stake -> acquired outright by Bora Pharmaceuticals Co., Ltd. (Taiwan), closed 2024, making Upsher-Smith a wholly-owned subsidiary of publicly listed Bora (TWSE: 6472, OTC: BORAY). Current ultimate owner is public. Sources: https://clinicaltrials.gov/study/NCT01142193 ; https://api.gleif.org/api/v1/lei-records/549300BJKGMHVWKZWS60 ; https://www.upsher-smith.com/news/sawai-pharmaceutical-completes-acquisition-of-upsher-smith-laboratories-generics-business/ ; https://bora-corp.com/bora-pharmaceuticals-to-acquire-us-pharma-manufacturer-upsher-smith-for-210-million-in-transaction-to-fuel-global-expansion/ ; https://stockanalysis.com/quote/tpe/6472/ Entity resolved by asset-pipeline-v2.)
Public Market Listing
Live quotes, historical charts, and market capitalization for Upsher-Smith Laboratories, LLC are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
Topiramate (Qudexy XR)(Qudexy XR) | Approved | Voltage-gated sodium channels, GABA-A receptor, AMPA/kainate glutamate receptors (multi-target)Small molecule | Epilepsy |
Vigabatrin (Vigafyde)(Vigafyde) | Approved | GABA transaminase (GABA-T)Small molecule | Epilepsy |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.